Ascendis Pharma A/S (ASND)

The latest pay-versus-performance read is still loading. and shareholder return moved -41.3 pts over the latest comparable period. The charts below show whether compensation tracked shareholder outcomes or drifted away from them.

Over the latest 12-month window, Ascendis Pharma A/S insiders show $26.9M of open-market sales across 4 trades. 0% of realized sales were pre-planned. There is 1 planned sale scheduled in the next 90 days. Use the sections below to separate executive-specific trades, company-wide activity, and upcoming planned sales.

This section contains the raw compensation tables behind the page: grant reconciliation, realized pay adjustments, pay-versus-performance disclosures, and the historical executive pay table. Use it when you want to verify the headline numbers, trace a year-over-year move, or cite the filing data directly in research.